PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA says ‘not yet’ to Praxis epilepsy drug

The FDA has placed a clinical hold on Praxis Precision Medicine’s new epilepsy drug.

While the reasons have not been shared yet, according to a regulatory filing, the company’s Investigational New Drug Application for the study of PRAX-222, a therapeutic for the treatment of patients with SCN2A gain-of-function mutations, was placed on clinical hold via an emailed letter from the FDA on April 28th.

The agency’s ‘not yet’ will be explained in a letter to Praxis within 30 days.

PRAX-222 is meant to treat patients with early-onset seizures. The drug is an antisense oligonucleotide, a form of therapy meant to target messenger RNA and alter expression. In 2020, more than 50 antisense therapy drug candidates were in clinical trials.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026